Danh mục
Nạp tiền Tải xuống 0

Tất cả tài liệu

Sắp xếp:
  • Mới nhất
  • Xem nhiều nhất
  • Tải nhiều nhất

HoSAGE: Sarcopenia in older patient with intermediate / high-risk prostate cancer, prevalence and incidence after androgen deprivation therapy: Study protocol for a cohort trial

HoSAGE: Sarcopenia in older patient with intermediate / high-risk prostate cancer, prevalence and incidence after androgen deprivation therapy: Study protocol for a cohort trial

12 0 0
7 trang
Protocol for a phase III RCT and economic analysis of two exercise delivery methods in men with PC on ADT

Protocol for a phase III RCT and economic analysis of two exercise delivery methods in men with PC on ADT

12 0 0
18 trang
Effects of once-yearly zoledronic acid on bone density and incident vertebral fractures in nonmetastatic castrationsensitive prostate cancer patients with osteoporosis

Effects of once-yearly zoledronic acid on bone density and incident vertebral fractures in nonmetastatic castrationsensitive prostate cancer patients with osteoporosis

9 0 0
7 trang
A phase II randomized controlled trial of three exercise delivery methods in men with prostate cancer on androgen deprivation therapy

A phase II randomized controlled trial of three exercise delivery methods in men with prostate cancer on androgen deprivation therapy

11 0 0
11 trang
The role of the methyltransferase METTL3 in prostate cancer: A potential therapeutic target

The role of the methyltransferase METTL3 in prostate cancer: A potential therapeutic target

15 0 0
16 trang
Treatment in the STAMPEDE era for castrate resistant prostate cancer in the UK: ongoing challenges and underappreciated clinical problems

Treatment in the STAMPEDE era for castrate resistant prostate cancer in the UK: ongoing challenges and underappreciated clinical problems

12 0 0
10 trang
SPARKLE: A new spark in treating oligorecurrent prostate cancer: Adding systemic treatment to stereotactic body radiotherapy or metastasectomy: Key to long-lasting event-free survival?

SPARKLE: A new spark in treating oligorecurrent prostate cancer: Adding systemic treatment to stereotactic body radiotherapy or metastasectomy: Key to long-lasting event-free survival?

9 0 0
10 trang